Results 271 to 280 of about 325,450 (339)

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta   +13 more
wiley   +1 more source

Causal relationship between immune cells and idiopathic thrombocytopenic purpura: A bidirectional Mendelian randomization study

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Heyi Zhang   +9 more
wiley   +1 more source

Single Cell Analysis Reveals Dynamic Changes of Distinct Cell Populations in Human Nickel Allergy

open access: yesAllergy, EarlyView.
We investigated cell types mediating the early and late inflammatory responses in human Ni2+‐allergy by scRNA‐Seq. Early responsiveness was mainly mediated by TLR4+TAGLN− endothelial cells indirectly activating TLR4−KRT16+ keratinocytes, and CCR7+DCN+ DCs. Late responsiveness was crucially driven by infiltration of KLF2+ central memory T cells and TLR4+
Marc Schmidt   +7 more
wiley   +1 more source

Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients. [PDF]

open access: yes, 1991
Dummer, JS   +8 more
core  

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Avapritinib and corticosteroids in advanced systemic mastocytosis with tumoral CMML and associated thrombocytopenia. [PDF]

open access: yesOxf Med Case Reports
Abakarim O   +7 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy